Clinical Study
Safety of Allogeneic Umbilical Cord Blood Stem Cells Therapy in Patients with Severe Cerebral Palsy: A Retrospective Study
Table 2
Analysis of blood test before and after allogeneic UCBSCs treatment.
| | Parameter | Before treatment () (%) | After treatment () (%) | value (two sides) | Reference range |
| | Leukocytes | 8 (17.0%) | 13 (27.7%) | 0.322 | (5.0~12.0) × 109/L | | Erythrocytes | 3 (6.4%) | 8 (17.0%) | 0.198 | (4.0~5.5) × 1012/L | | Haemoglobin | 5 (10.6%) | 7 (14.9%) | 0.759 | (110.0~150.0) g/L | | Platelets | 29 (61.7%) | 23 (48.9%) | 0.300 | (100.0~300.0) × 109/L | | ALT | 3 (6.4%) | 5 (10.6%) | 0.714 | (9~50.0) U/L | | AST | 6 (12.8%) | 5 (10.6%) | 1.000 | (15~40.0) U/L | | BUN | 8 (17.0%) | 6 (12.8%) | 0.773 | (1.43~6.78) mmol/L | | SCR | 2 (4.3%) | 2 (4.3%) | 1.000 | (16.0~73.0) umol/L | | K+ | 3 (6.4%) | 5 (10.6%) | 0.714 | (3.5~5.3) mmol/L | | Na+ | 6 (12.8%) | 10 (21.3%) | 0.206 | (137.0~147.0) mmol/L | | CL− | 4 (8.5%) | 5 (10.6%) | 1.000 | (99.0~110.0) mmol/L | | TCO2 | 16 (34.0%) | 13 (27.7%) | 0.656 | (20.0~28.0) mmol/L | | Glu | 3 (6.4%) | 2 (4.3%) | 1.000 | (3.9~6.1) mmol/L | | PT | 4 (8.5%) | 4 (8.5%) | 1.000 | (10.0~13.0) s | | APTT | 11 (23.4%) | 10 (21.3%) | 1.000 | (22.0~32.0) s | | INR | 1 (2.1%) | 3 (6.4%) | 0.308 | 0.8–1.2 | | FIB | 5 (10.6%) | 8 (17.0%) | 0.552 | (2.0~4.0) g/L |
|
|
The numbers (percentage) of patients whose blood test result was abnormal; UCBSCs: umbilical cord blood stem cells; ALT: alanine aminotransferase; AST: aspartate aminotransferase; BUN: serum urea nitrogen; SCR: serum creatinine; K+: serum potassium; Na+: serum sodium; CL−: serum chloride ion; TCO2: total carbon dioxide; Glu: serum glucose; PT: prothrombin time; APTT: activated partial thromboplastin time; INR: international normalized ratio; FIB: fibrinogen.
|
